|
1
|
Cai JQ, Cai SW, Cong WM and Chen MS:
Diagnosis and treatment of cholangiocarcinoma: A consensus from
surgical specialists of China. J Huazhong Univ Sci Technolog Med
Sci. 34:469–475. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ponting CP, Oliver PL and Reik W:
Evolution and functions of long noncoding RNAs. Cell. 136:629–641.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Salmena L, Poliseno L, Tay Y, Kats L and
Pandolfi P: A ceRNA hypothesis: The Rosetta stone of a hidden RNA
language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Spizzo R, Almeida MI, Colombatti A and
Calin GA: Long non-coding RNAs and cancer: A new frontier of
translational research? Oncogene. 31:4577–4587. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang Z, Zhou L, Wu LM, Lai MC, Xie HY,
Zhang F and Zheng SS: Overexpression of long non-coding RNA HOTAIR
predicts tumor recurrence in hepatocellular carcinoma patients
following liver transplantation. Ann Surg Oncol. 18:1243–1250.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou X, Liu J and Wang W: Construction and
investigation of breast-cancer-specific ceRNA network based on the
mRNA and miRNA expression data. Let Syst Biol. 8:96–103. 2014.
|
|
7
|
Arun K, Arunkumar G, Bennet D,
Chandramohan SM, Murugan AK and Munirajan AK: Comprehensive
analysis of aberrantly expressed lncRNAs and construction of ceRNA
network in gastric cancer. Oncotarget. 9:18386–18399. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou M, Diao Z, Yue X, Chen Y, Zhao H,
Cheng L and Sun J: Construction and analysis of dysregulated
lncRNA-associated ceRNA network identified novel lncRNA biomarkers
for early diagnosis of human pancreatic cancer. Oncotarget.
7:56383–56394. 2016.PubMed/NCBI
|
|
9
|
Peng H, Lu M and Selaru FM: The
genome-wide gene expression profiling to predict competitive
endogenous RNA network in hepatocellular cancer. Genomics Data.
4:93–95. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shi X, Zhang H, Wang M, Xu X, Zhao Y, He
R, Zhang M, Zhou M, Li X, Peng F, et al: LncRNA AFAP1-AS1 promotes
growth and metastasis of cholangiocarcinoma cells. Oncotarget.
8:58394–58404. 2017.PubMed/NCBI
|
|
11
|
Zhang S, Xiao J, Chai Y, Du YY, Liu Z,
Huang K, Zhou X and Zhou W: LncRNA-CCAT1 promotes migration,
invasion, and EMT in intrahepatic cholangiocarcinoma through
suppressing miR-152. Dig Dis Sci. 62:3050–3058. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chan WL, Huang HD and Chang JG: lncRNAMap:
A map of putative regulatory functions in the long non-coding
transcriptome. Comput Biol Chem. 50:41–49. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Robinson MD, McCarthy DJ and Smyth GK:
edgeR: A Bioconductor package for differential expression analysis
of digital gene expression data. Bioinformatics. 26:139–140. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ashwini J, Marks DS and Erik L: miRcode: A
map of putative microRNA target sites in the long non-coding
transcriptome. Bioinformatics. 28:2062–2063. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chou CH, Shrestha S, Yang CD, Chang NW,
Lin YL, Liao KW, Huang WC, Sun TH, Tu SJ, Lee WH, et al: miRTarBase
update 2018: A resource for experimentally validated
microRNA-target interactions. Nucleic Acids Res. 46:D296–D302.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wong N and Wang X: miRDB: An online
resource for microRNA target prediction and functional annotations.
Nucleic Acids Res. 43:D146–D152. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:2015. View Article : Google Scholar
|
|
18
|
Li YY, Li H, Lv P, Liu G, Li XR, Tian BN
and Chen DJ: Prognostic value of cirrhosis for intrahepatic
cholangiocarcinoma after surgical treatment. J Gastrointest Surg.
15:608–613. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Batista PJ and Chang HY: Long Noncoding
RNAs: Cellular address codes in development and disease. Cell.
152:1298–1307. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng B, Jeong S, Zhu Y, Chen L and Xia Q:
miRNA and lncRNA as biomarkers in cholangiocarcinoma(CCA).
Oncotarget. 8:100819–100830. 2017.PubMed/NCBI
|
|
21
|
Huang QX, Cui JY, Ma H, Jia XM, Huang FL
and Jiang LX: Screening of potential biomarkers for
cholangiocarcinoma by integrated analysis of microarray data sets.
Cancer Gene Ther. 23:48–53. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang W, Li Y, Song X, Xu J and Xie J:
Genome-wide analysis of long noncoding RNA and mRNA co-expression
profile in intrahepatic cholangiocarcinoma tissue by RNA
sequencing. Oncotarget. 8:26591–26599. 2017.PubMed/NCBI
|
|
23
|
Sun H, Wang G, Peng Y, Zeng Y, Zhu QN, Li
TL, Cai JQ, Zhou HH and Zhu YS: H19 lncRNA mediates
17β-estradiol-induced cell proliferation in MCF-7 breast cancer
cells. Oncol Rep. 33:3045–3052. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li L, Chen W, Wang Y, Tang L and Han M:
Long non-coding RNA H19 regulates viability and metastasis, and is
upregulated in retinoblastoma. Oncol Lett. 15:8424–8432.
2018.PubMed/NCBI
|
|
25
|
Yang F, Bi J, Xue X, Zheng L, Zhi K, Hua J
and Fang G: Up-regulated long non-coding RNA H19 contributes to
proliferation of gastric cancer cells. FEBS J. 279:3159–3165. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu C, Chen Z, Fang J, Xu A, Wei Z and
Wang Z: H19-derived miR-675 contributes to bladder cancer cell
proliferation by regulating p53 activation. Tumor Biol. 5:263–270.
2016. View Article : Google Scholar
|
|
27
|
Liang WC, Fu WM, Wong CW, Wang Y, Wang WM,
Hu GX, Zhang L, Xiao LJ, Wan DC, Zhang JF and Waye MM: The lncRNA
H19 promotes epithelial to mesenchymal transition by functioning as
miRNA sponges in colorectal cancer. Oncotarget. 6:22513–22525.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu Y, Wang Z, Jiang X and Cui Y:
Overexpression of long noncoding RNA H19 indicates a poor prognosis
for cholangiocarcinoma and promotes cell migration and invasion by
affecting epithelial-mesenchymal transition. Biomed Pharmacother.
92:17–23. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Boonyanugomol W, Chomvarin C, Sripa B,
Bhudhisawasdi V, Khuntikeo N, Hahnvajanawong C and Chamsuwan A:
Helicobacter pylori in Thai patients with cholangiocarcinoma
and its association with biliary inflammation and proliferation.
HPB (Oxford). 14:177–184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang WT, Ye H, Wei PP, Han BW, He B, Chen
ZH and Chen YQ: LncRNAs H19 and HULC, activated by oxidative
stress, promote cell migration and invasion in cholangiocarcinoma
through a ceRNA manner. J Hematol Oncol. 9:1172016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhou DD, Liu XF, Lu CW, Pant OP and Liu
XD: Long non-coding RNA PVT1: Emerging biomarker in digestive
system cancer. Cell Prolif. 50:e123982017. View Article : Google Scholar
|
|
32
|
Wan L, Sun M, Liu GJ, Wei CC, Zhang EB,
Kong R, Xu TP, Huang MD and Wang ZX: Long non-coding RNA PVT1
promotes non-small cell lung cancer cell proliferation through
epigenetically regulating LATS2 expression. Mol Cancer Ther.
15:1082–1094. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shuang Y, Ning Q, Zhang G, Hong S, Zhen W
and Li Y: Construction of differential mRNA-lncRNA crosstalk
networks based on ceRNA hypothesis uncover key roles of lncRNAs
implicated in esophageal squamous cell carcinoma. Oncotarget.
7:85728–85740. 2016.PubMed/NCBI
|
|
34
|
Zheng J, Yu F, Dong P, Wu L, Zhang Y, Hu Y
and Zheng L: Long non-coding RNA PVT1 activates hepatic stellate
cells through competitively binding microRNA-152. Oncotarget.
7:62886–62897. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang C, Yu W, Wang Q, Cui H, Wang Y,
Zhang L, Han F and Huang T: Increased expression of the lncRNA PVT1
is associated with poor prognosis in pancreatic cancer patients.
Minerva Med. 106:143–149. 2015.PubMed/NCBI
|
|
36
|
Lu D, Luo P, Wang Q, Ye Y and Wang B:
lncRNA PVT1 in cancer: A review and meta-analysis. Clin Chim Acta.
474:1–7. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Semple RK, Chatterjee VK and O'Rahilly S:
PPAR gamma and human metabolic disease. J Clin Invest. 116:581–589.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Colincassin C, Yao X, Cerella C, et al:
PPAR, breast cancer. Molecular Carcinogenesis. 54:393–404.
2013.PubMed/NCBI
|
|
39
|
Morgado M and Carson DD: PPARγ Modulation
of cytokine-stimulated MUC16 (CA125) expression in breast and
ovarian cancer-derived cells. J Cell Biochem. 118:163–171. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu D, Davis BB, Wang ZH, Zhao SP, Wasti B,
Liu ZL, Li N, Morisseau C, Chiamvimonvat N and Hammock BD: A potent
soluble epoxide hydrolase inhibitor, t-AUCB, acts through PPARγ to
modulate the function of endothelial progenitor cells from patients
with acute myocardial infarction. Int J Cardiol. 167:1298–1304.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Han C, Demetris AJ, Michalopoulos GK, Zhan
Q, Shelhamer JH and Wu T: PPARgamma ligands inhibit
cholangiocarcinoma cell growth through p53-dependent GADD45 and p21
pathway. Hepatology. 38:167–177. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tennis MA, Van Scoyk MM, Freeman SV,
Vandervest KM, Nemenoff RA and Winn RA: Sprouty-4 inhibits
transformed cell growth, migration and invasion, and
epithelial-mesenchymal transition, and Is Regulated by Wnt7A
through PPARgamma in non-small cell lung cancer. Mol Cancer Res.
8:833–843. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Han C, Demetris AJ, Liu Y, Shelhamer JH
and Wu T: Transforming growth factor-β (TGF-β) activates cytosolic
phospholipase A2α (cPLA2α)-mediated prostaglandin E2 (PGE)2/EP1 and
peroxisome proliferator-activated receptor-γ (PPAR-γ)/Smad
signaling pathways in human liver cancer cells. JBC. Aug
4–2004.(Epub ahead of print). doi: 10.1074/jbc.M404852200.
View Article : Google Scholar
|
|
44
|
Reka AK, Kurapati H, Narala VR, Bommer G,
Chen J, Standiford TJ and Keshamouni VG: Peroxisome
proliferator-activated receptor-gamma activation inhibits tumor
metastasis by antagonizing Smad3-mediated epithelial-mesenchymal
transition. Mol Cancer Ther. 9:3221–3232. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Suzuki S, Mori J, Yamazaki M, Sato A,
Hosoda W and Hashizume K: Beneficial effects of pioglitazone on
cholangiohepatitis induced by bile duct carcinoma. Internal Med.
46:1723–1727. 2007. View Article : Google Scholar
|
|
46
|
Asukai K, Kawamoto K, Eguchi H, Konno M,
Asai A, Iwagami Y, Yamada D, Asaoka T, Noda T, Wada H, et al:
Micro-RNA-130a-3p Regulates Gemcitabine resistance via PPARG in
cholangiocarcinoma. Ann Surg Oncol. 24:2344–2352. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Nagaraj NS and Singh OV: Integrating
genomics and proteomics-oriented biomarkers to comprehend lung
cancer. Expert Opin Med Diagn. 3:167–180. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wang A, Lu C, Ning Z, Gao W, Xie Y, Zhang
N, Liang J, Abbasi FS, Yan Q and Liu J: Tumor-associated
macrophages promote Ezrin phosphorylation-mediated
epithelial-mesenchymal transition in lung adenocarcinoma through
FUT4/LeY up-regulation. Oncotarget. 8:28247–28259. 2017.PubMed/NCBI
|
|
49
|
Li Y, Sun Z, Liu B, Shan Y, Zhao L and Jia
L: Tumor-suppressive miR-26a and miR-26b inhibit cell
aggressiveness by regulating FUT4 in colorectal cancer. Cell Death
Dis. 8:e28922017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wong KK, Gascoyne DM, Brown PJ, Soilleux
EJ, Snell C, Chen H, Lyne L, Lawrie CH, Gascoyne RD, Pedersen LM,
et al: Reciprocal expression of the endocytic protein HIP1R and its
repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large
B-cell lymphoma patients. Leukemia. 28:362–372. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Rice MA, Ishteiwy RA, Magani F, Udayakumar
T, Reiner T, Yates TJ, Miller P, Perez-Stable C, Rai P, Verdun R,
et al: The microRNA-23b/-27b cluster suppresses prostate cancer
metastasis via Huntingtin-interacting protein 1-related. Oncogene.
35:4752–4761. 2016. View Article : Google Scholar : PubMed/NCBI
|
